Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiMO-301 with hypofractionated radiotherapy and PD-1 inhibitor in head and neck cancer
NCT05838729Phase 2Recruiting
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RiMO-301 in head and neck cancer (HNC), sponsored by Coordination Pharmaceuticals, Inc.. Started Apr 2023; status: recruiting.
02
Drugs
RiMO-301
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05838729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838729.